雷帕霉素和顺铂对Hep-2细胞DNA切除修复交叉互补基因1表达的协同作用

摘要

[ Objective ] To investigate the cytotoxic effect and mechanism of action of cisplatin and the mTOR inhibitor rapamycin on laryngeal cancer (Hep2) cells. [Methods] Hep-2 cells were cultured in the presence of different concentrations of rapamycin, cisplatin or the two combined. A subset of cells was treated with rapamycin only at concentrations of 5 and 20 μmol/L. A further subset of cells was treated with cisplatin only at concentrations of 3 and 12 μmol/L. A final subset of cells was treated with media containing 5 μmol/L rapamycin and 3 μmol/L cisplatin combined. Western blot was used to determine expression of proteins p-Akt, p-mTOR, S6K, and ERCC-1 in 3, 6, 12, 24, and 48 h. [Results] mTOR, S6K and ERCC-1 protein levels significantly decreased after treating with rapamycin 12 h. AKT protein levels significantly increase after treating with rapamycin 48 h. ERCC-1 protein levels significantly increase after treating with cisplatin 12 h. No changes in AKT, p-mTOR and S6K protein expression were apparent for treating with cisplatin. S6K and p-mTOR protein levels significantly decreased after treating with combined drug 12 h. AKT protein levels significantly increase after 48 h. No changes in ERCC-1 protein expression were apparent for this treatment group.[Conclusions] The synergistic effect of rapamycin and cisplatin improves their cytotoxicity on Hep2 cells. The expression of ERCC-1 influencing by rapamycin might be related to this.%[目的]探讨mTOR抑制剂雷帕霉素和顺铂对喉癌Hep-2细胞协同作用的机制。[方法]Hep-2细胞在雷帕霉素单药浓度为5、20 μmol/L；顺铂单药浓度为3、12 μmol/L；联合用药浓度为雷帕霉素5 μmol/L联合顺铂3 μmol/L中分别培养，检测Hep-2细胞AKT，mTOR，S6K和ERCC1(DNA切除修复交叉互补基因1)蛋白分别在3，6，12，24，48 h的表达情况。[结果]雷帕霉素单药干预Hep-2细胞12 h后，p-mTOR、S6K及ERCC-1表达表达下调，与对照组比较显著性,AKT蛋白表达在48 h增加，与对照组比较差异有统计学意义；顺铂单药干预Hep-2细胞时，ERCC-1表达12 h后增加，与对照组比较差异有统计学意义，p-mTOR、AKT和S6K蛋白表达差异无统计学意义；联合用药时，AKT蛋白表达在48 h增加，与对照组比较差异有统计学意义，p-mTOR、S6K、在12 h后表达下降，与对照组比较差异有统计学意义，ERCC-1的表达与对照组比较没有差异有统计学意义。[结论]雷帕霉素和顺铂联合应用时，呈协同作用，这可能与雷帕霉素能诱导肿瘤细胞凋亡及影响ERCC-1的表达有关。